Expert Interview
Examining the clinical landscape of renal disease and the potential of anticoagulant therapies in this space for the prevention of cardiovascular events, including Merck's MK-2060.
Ticker(s): MRKInstitution: Upstate Medical University
- Professor of Internal Medicine, Surgery, and Pediatrics; Medical Director of Dialysis at Norton College of Medicine at Upstate Medical University.
- Sees 300 patients a month with renal disease, with 100 being on dialysis (ESRD).
- Clinical Research includes projects exploring cardiovascular disease in patients with chronic kidney disease and development of a non-invasive blood analyte sensing device.
Please describe your background and practice setting
Added By: ben_adminHow many patients with renal disease do you treat monthly?
Added By: ben_adminHow many of your patients will experience major thrombotic cardiovascular events?
Added By: ben_adminWhat current medications do you use to prevent major thrombotic cardiovascular events?
Added By: ben_adminAre you familiar with Factor 11a inhibitors? What potential do they bring to limiting bleeding in patients compared to factor 10a inhibitors?
Added By: ben_adminWhat were your overall thoughts about Merck's MK-2060 study and its potential? Do most ESRD patients tend to have underlying conditions like diabetes, high blood pressure, atrial fibrillation, and cardiovascular disease that increase their risk of blood clots? Is this a large unmet need?
Added By: ben_adminAre you familiar with Bayer and Ionis antisense-based Factor XI inhibitor, fesomersen?
Added By: ben_adminDo a large percentage of your patients experience increased bleeding due to other anticoagulation medications? What % of decrease in clotting factors meets your threshold for positivity?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
